About Clear Creek Bio
Clear Creek Bio is a private, clinical-stage biotech company focused on developing novel therapies to address infectious disease and cancer. The company’s lead drug candidate, brequinar, is a dihydroorotate dehydrogenase (DHODH) inhibitor with oral bioavailability and high potency. Clear Creek Bio is evaluating brequinar in clinical trials as a potential once-daily treatment for COVID-19. The company is also assessing brequinar as a potential treatment for acute myeloid leukemia.
Brequinar: A potential treatment for COVID-19 and beyond
Brequinar blocks de novo pyrimidine biosynthesis, which is essential for DNA and RNA synthesis. In vitro and in vivo studies have shown that brequinar has potent antiviral activity against a wide range of viruses, including SARS-CoV-2, the novel coronavirus that causes COVID-19. Because brequinar acts on the host cell, it has the potential to deliver mutation-resistant antiviral activity either as a standalone therapy or combined to complement and enhance direct-acting antiviral drugs, such as nucleoside analogs. Clear Creek Bio is focused on rapidly developing brequinar as a potential treatment for COVID-19 and to establish it as a broad-spectrum antiviral to be available in advance of future outbreaks for pandemic preparedness.